Accepted for/Published in: JMIR Research Protocols
Date Submitted: Oct 16, 2025
Date Accepted: Jan 19, 2026
(closed for review but you can still tweet)
Protocol for a Before-and-After Intervention Study to Assess the Implementation of a Personalized Medicine Approach in Patients With Type 2 Diabetes Mellitus on Multiple Daily Insulin Injections (POMA Project)
ABSTRACT
Background:
The management of type 2 diabetes mellitus (T2DM) remains a complex clinical challenge, particularly for patients requiring multiple daily insulin injections (MDI). Advances in precision medicine and continuous glucose monitoring (CGM) have created opportunities to personalize treatment and potentially reduce the therapeutic burden on people with T2DM. Assessing beta-cell function and autoimmunity could help identify patients with T2DM eligible for simplified regimens without compromising glycemic control.
Objective:
The aim of this study was to test a simple personalized medicine protocol in routine clinical practice for people with T2DM treated with MDI. The intervention is based on the evaluation of C-peptide and glutamic acid decarboxylase autoantibody (GADAb) status, with the goal of improving diagnostic accuracy and optimizing treatment.
Methods:
This is a pragmatic, before-and-after intervention study involving people with T2DM on current MDI across primary care centers and a referral hospital in the Lleida health care region, Catalonia (Spain). Eligible participants will undergo clinical and laboratory assessment, including C-peptide and GADAb testing, and wear a CGM device. Based on a predefined algorithm, patients may either continue or discontinue prandial insulin. The primary outcome is the proportion of patients in whom prandial insulin is discontinued and remains discontinued over 6 months. Secondary outcomes include changes in glycated haemoglobin (HbA1c), CGM metrics variables, quality of life, adherence, and treatment satisfaction.
Results:
Recruitment was completed on March 31, 2025. The follow-up phase is ongoing and expected to conclude by September 30, 2025. Data analysis will begin thereafter.
Conclusions:
This study will evaluate the feasibility and impact of implementing a personalized therapeutic approach for persons with T2DM on MDI in real-world clinical settings. If effective, this strategy could contribute to safer, simpler, and more individualized diabetes care. Clinical Trial: ClinicalTrials.gov NCT06148376; https://clinicaltrials.gov/ct2/show/NCT06148376
Citation
Request queued. Please wait while the file is being generated. It may take some time.